Halozyme Q3 top line up 80%, guidance cut

Halozyme (NASDAQ:HALO) Q3 results:

Revenues: $46.2M (+80%) increase mainly due to bulk rHuPH20 sales to Janssen of $20.1M.

Net loss: ($25.0M) (+10%); loss/share: ($0.17) (+11%).

2019 guidance: Revenues: $195M -205M from $205M – 215M.

Previously: Halozyme Therapeutics EPS misses by $0.05, misses on revenue (Nov. 12)

https://seekingalpha.com/news/3518245-halozyme-q3-top-line-80-percent-guidance-cut